- Hifas da Terra (HDT) and the Galicia Sur Biomedical Foundation They have driven a Clinical trial In colorectal cancer To evaluate the new natural formula Mico-Digest 2.0 in 144 patients. This is the First clinical study in Spain made with compounds derived from fungus.
- The objective of the clinical trial in colorectal cancer is to study whether the Taking this nutraceutical reduces postoperative complications derived from surgical intervention that affect 20% of patients.
- This study, which is currently carried out in the Ourense University Hospital, It is part of the final phase of the Micromarker I+D Collaborative Project, co-dried by the multinational biotech of Galician origin Hifas da Terra, and has the support of the CDTI, the financing mediator of the General Administration of the State of the R&D.
- Hifas Da Terra was founded in 1998 by the hand of Catalina Fernández de Ana Portela, Biologist, Mycologist and in a Doctorate Program in Oncological Clinical Research at the University of Santiago de Compostela. The company, a Pioneer biotechnological project Born in Galicia, he has become International leader in the development of supplements for human health based on fungi.
Hifas da Terra has promoted, in collaboration with the Galicia Sur Biomedical Foundation, a clinical trial with Mico-Digest 2.0, the natural formula prepared by the Galician company, which already works within this study as a natural immunomodulator. Specifically, the essay includes One of the most innovative products of Hifas da Terra since it contains a high concentration of natural bioactive compounds obtained from medicinal fungal extracts. This study, registered in the International Portal clinicaltrials.gov, will evaluate the impact of myco-digest 2.0 supplementation in relation to the rate of postoperative complications, as well as the modification of the microbiota, the reduction of inflammatory parameters and digestive well-being, aspects related to the immune response of patients.
He Ethics Committee of the Research of Pontevedra-Vigo-Ourense authorized this clinical trial in summer, Promoted by the Galicia Sur Biomedical Foundation in which, for the first time, a Nutraceutic of Hifas da Terra elaborated from a synergistic combination of several medicinal fungi extracts is included, whose objective is the Reduction of the risk of postoperative complications in the patient with colorectal cancer under surgery.
Fungal polysaccharides have attracted attention to their role in the modulation of the intestinal microbiota. It seems that this type of polysaccharides could reduce pathogen levels and stimulate the growth of beneficial microorganisms. Its anti -inflammatory activity has also been described. The combination of different fungal extracts would send multiple stimuli to the immune system by increasing intracellular reactions and interactions. Therefore, the Micodigest 2.0 fungal extract nutraceutical could be used to reduce complications after colorectal cancer surgery.
The study, whose full title is Double blind randomized closing trial to evaluate the effect of the administration of the nutraceutical Micodigest 2.0 prior to the intervention in the complications associated with the surgery of colorectal cancer treated with healing intention, It is a pioneering essay in the oncological field. In this clinical study, how the prebiotic and anti -inflammatory effects of Mico-Digest 2.0 of Hifas da Terra, They can reduce postoperative complications that affect 20% of patients who undergo surgical intervention.
As explained from the Department of R&D of Hifas da Terra, these complications also constitute A risk factor for disease recurrence in different types of neoplasms. "We know that the bacteria present in the microbiota could play an important role in the prevention of colorectal cancer. In this study we will observe the repercussions at the inflammatory level resulting from the modification of the microbiota," they say. "We hope that the application of Myco-Digest 2.0 nutraceutical, due to its anti-inflammatory effects and microbiota modulator, act positively in the patient's immune response, ”they add.
This study is part of the final phase of the I+D Micromarker collaborative project, which began in 2018, and has evaluated through different phases prior to the test in patients the relationship between the modulation of the intestinal microbiota and the progression of colorectal cancer in own studies.
The results of these initial phases allowed the formulation of the extracts with better prebiotic and anti -inflammatory activity demonstrated In vitro. The conclusions They have resulted in the development of the new formula that will be evaluated in patients in the trial whose production process will be protected under patent, after a favorable report from the Spanish Patent and Brands Office.
From Hifas da Terra They explain that, although Certain genetic factors contribute to the appearance of colorectal cancer, microbiota or intestinal flora seems to have an important role in its development and progression and in the quality of life of these patients. Dysbiosis or imbalance of microorganisms present in normal microbiota is a common feature in patients with colon and rectum cancer, and inflammation are two of the most important mechanisms in relation to the disease.
The microbiota or intestinal flora is the set of microorganisms that live, regularly, in the intestine of human beings, maintaining a symbiotic relationship. Most are bacteria that maintain a delicate balance with the rest of microorganisms and They are beneficial for the body, since they participate in numerous physiological processes such as the metabolism of some carbohydrates, the activation of the immune system, the regulation of the growth of intestinal cells and the synthesis of certain vitamins, such as B and the K.
And, a poor intestinal microbiota can contribute to the development of cancer and various metabolic disorders that lead to inflammation in the intestine, liver and brain. Studies show that medicinal fungi influences the microbiota But controlled clinical trials are required in patients such as this one who help to fully understand their multiple benefits in cancer and in human health.
Through this clinical trial, analytical data related to inflammatory markers and other data related to digestive well-being will be obtained, before and after the supplementation with myco-digest 2.0 .. “we have already studied the effect of fungi on the immune system, but this new study will allow to assess its capacity in the modification of the intestinal microbiota and how the fungal extracts act certain markers such as inflammation, ”says Catalina Fernández de Ana, founder and president of the Biotech.
Hifas da Terra, Research as Pilar of the Company
Catalina Fernández de Ana Portela He is responsible for the success of the Hifas da Terra company that, as Founder and PresidentApplies a Know How, based on more than 20 years of experience, together with a broad and international team of experts. To know the origin of the company it is necessary to go back to 1998 when he was born. Hifas da Terra It is a Biotech that is based on research and innovation, with a high degree of specialization, on the development of nutraceutics from medicinal fungi.
He Treatment with medicinal fungi Its objective is the research and development of Natural products For maintenance and Improvement of human health. Hifas Da Terra's commitment to health and well -being translates into research and innovation for product development as nutraceutical, medical devices and biopharmacus high quality and added value for the Integrative treatment of pathologies.
The Research Areas most important in HDT are studies on gastroenterology, oncology, immunology, musculoskeletal system and mental-emotional health. Currently, Hifas da Terra has more than 15 active clinical studies that evaluate the health benefits of the supplementation of their products, including 2 oncological clinical trials such as this in patients with Colorectal cancer (Micromarker), another in Breast cancer (Microimmunomama), 2 highly innovative clinical trials in the area of the Women's health and clinical studies in patients with Sibo in it Irritable intestine syndrome, Dao deficiency and diverticular disease, among others.
The enormous commitment of Hifas da Terra with the environment is something that is confirmed with Hifas and Hifas Foundation Foundation, non -profit entities that make up the Hifas Da Terra Group and that work for health and the environment, respectively.
Such is the success of its products that, today, this company of Galician origin Export and market its products in Spain, France, Portugal, Italy, United Kingdom, Germany, China and soon in the United States. Health professionals from different countries trust Hifas Da Terra formulas, forming a multidisciplinary prescription network of more than 10,000 experts with those who collaborate through its subsidiaries and distributors in Europe, the United States, the Middle East and new emerging countries.